Russia's Sputnik V COVID-19 Vaccine Shows 95% Efficacy

Moreover, the Sputnik V vaccine will be reportedly cheaper than its rivals.
Derya Ozdemir

As the race for a people's vaccine against COVID-19 picks up speed, more and more developers are announcing their efficacy results.

In breaking news, Russia's Sputnik V COVID-19 vaccine has been found to be 95% effective according to a second interim analysis of clinical trial data, as reported by its developers on Tuesday. 

According to the joint statement made by Russia's health ministry, Gamaleya Scientific Research Institute, and the Russian Direct Investment Fund (RDIF), the calculations were based on preliminary data, collected 42 days after the volunteers took the first dose.

The number of cases used to make the calculation wasn't disclosed. 

The vaccine had previously been reported to show 91.4% efficacy 28 days after the first dose was given to trial participants.

People who recently submitted requests will get the first batches of Sputnik V in March 2021

Russia has also stated that Sputnik V will cost less than Pfizer and Moderna's vaccine candidates, which have both shown impressive results in vaccine trials, per Frace 24.

Most recently, a statement on the official Sputnik V Twitter account announced that "The cost of one dose of the #SputnikV vaccine for the external market will be less than $10 (two doses per person is necessary) – two or more times cheaper than mRNA vaccines with similar efficacy levels (based on announced mRNA vaccines pricing & interim Phase III results)."